Filtered By:
Condition: Stroke
Management: Funding
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 633 results found since Jan 2013.
IDx Closer to Nod for Diabetic Retinopathy Diagnostic
Privately held IDx is developing an artificial intelligence-based system that could help with the diagnosis diabetic retinopathy – a disease that leads to blindness if undetected.
The company met its endpoints in a pivotal trial of the IDx-DR system. The trial involved 900 diabetes patients at 10 sites. The study was designed to evaluate the diagnostic accuracy of the technology in detecting moderate to severe diabetic retinopathy, including macular edema.
The results of the pivotal trial met the study hypotheses that were developed in consultation with FDA and demonstrated the IDx-DR system exceeded these performance go...
Source: MDDI - February 23, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Medical Device Business Source Type: news
Ischaemic stroke management at Al-Shifa Hospital in the Gaza Strip: a clinical audit
Publication date: 21 February 2018 Source:The Lancet, Volume 391, Supplement 2 Author(s): Amir Abukaresh, Rami Al-Abadlah, Bettina Böttcher, Khamis El-Essi Background In the 2014 Palestinian annual health report, cerebrovascular accident was ranked as the third leading cause of death in the occupied Palestinian territory. Cerebrovascular accident is also one the most common causes of disability worldwide. Good management decreases mortality and morbidity. The aim of this study was to assess the current management of patients with ischaemic stroke at the Al-Shifa Hospital and to compare this with international guidelines....
Source: The Lancet - February 23, 2018 Category: General Medicine Source Type: research
AI Solution Detects Autism in Toddlers
A digital healthcare startup is using an artificial intelligence (AI) platform to help aid in the detection of autism. Palo Alto, CA -based Cognoa said FDA has classified the algorithm-powered solution as a Class II diagnostic medical device.
The FDA designation gives the company a path to get full clearance as a medical diagnostic for autism.
“The goal actually is this summer to submit to the FDA to get full clearance under a de novo as a medical diagnostic,” Sharief Taraman, vice president of medical at Cognoa, told MD+DI. “I think we should be able to get that at the end of the year or by 2019.”
Network with y...
Source: MDDI - February 22, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Digital Health Source Type: news
Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million.
The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised a $40 million Series E round in May 2016.
The Mitralign and Trialign devices are designed to use wire and catheters to implant polyester anchors within the annulus of the mitral and tricuspid valves. The anchors are then cinched together to reduce v...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Mitralign Inc. Source Type: news
Perflow Medical closes $12m round to support Stream Net thrombectomy device
Israel-based neurovascular device developer Perflow Medical said it closed a $12 million round of financing to help support its Stream dynamic neuro-thrombectomy net designed for treating acute ischemic stroke.
Funding from the round will support the European commercialization of the company’s first product, the Stream Net device, and a 510(k) submission to the FDA in pursuit of US approval.
Funds will also help support development of two new products based off the company’s Cerebral Net technology platform for aneurysm neck bridging and flow diversion procedures.
The Stream Net device is designed to treat acut...
Source: Mass Device - February 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Neurological perflowmedical Source Type: news
A Review of Mathematical Models for Muscular Dystrophy: A Systems Biology Approach
Discussion
With new developments in computational power and data availability, a growing amount of research is using a systems biology approach to understand pathogenesis and progression of disease. Effective and integrated in vitro and in silico models could inform biological phenomena, even without the need of a living subject. For instance, over the last few decades, collagen hydrogel with muscle derived cells (CHMDCs) have promised to revolutionize in vitro experiments and tissue engineering. For CHMDCs to reach the envisioned use, verification by use of mathematical simulations are needed. Recently while examining sha...
Source: PLOS Currents Muscular Dystrophy - February 16, 2018 Category: Neurology Authors: Matthew Houston Source Type: research
FDA Approves First Blood Test to Help Diagnose Brain Injuries
(CHICAGO) — The first blood test to help doctors diagnose traumatic brain injuries has won U.S. government approval.
The move means Banyan Biomarkers can commercialize its test, giving the company an early lead in the biotech industry’s race to find a way to diagnose concussions.
The test doesn’t detect concussions and the approval won’t immediately change how patients with suspected concussions or other brain trauma are treated. But Wednesday’s green light by the Food and Drug Administration “is a big deal because then it opens the door and accelerates technology,” said Michael Mc...
Source: TIME: Health - February 15, 2018 Category: Consumer Health News Authors: Lindsey Tanner / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
NIH inks $5m partnership with PathMaker Neurosystems for MyoRegulator spasticity device
PathMaker Neurosystems said today it signed a $5 million cooperative partnership deal with the National Institutes of Health to support continued development of its MyoRegulator neurostimulation system designed to treat spasticity secondary to stroke.
The MyoRegulator device, based on PathMaker’s DoubleStim technology, is designed to provide simultaneous, non-invasive stimulation at spinal and peripheral locations, the Boston and Paris-based company said.
The money comes as part of a four-year grant awarded through the CREATE Devices program which also provides a partnership with the NIH’s National Institute of ...
Source: Mass Device - February 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neuromodulation/Neurostimulation PathMaker Neurosystems Inc. Source Type: news
Letter to the Editor: Pneumocephalus: Is the needle size significant?
Discussion. Pneumocephalus is defined by two mechanisms: a ball-valve and an inverted bottle concept.1 The ball-valve type implies positive pressure events, such as coughing or valsalva maneuvers, that prevent air escape. Tension pneumocephalus is included in this mechanism, causing a parenchymal mass effect. The inverted bottle theory includes a negative intracranial pressure gradient following cerebrospinal fluid drainage, relieved by air influx. A small pneumocephalus is usually sealed by blood clots or granulation, allowing spontaneous reabsorption and resolution.[1] Otherwise, the lateral positioning of a patient duri...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Assessment Tools CNS Infections Current Issue Letters to the Editor Neurologic Systems and Symptoms Neurology Stroke Traumatic Brain Injury epidural needle size Pneumocephalus spinal tap Source Type: research
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published ...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research
Dr. Boukrina of Kessler Foundation explores treatments for reading deficits after stroke
(Kessler Foundation) 'The Trust's funding has enabled us identify people by type of reading problem, i.e., whether their primary problem is with word appearance, word meaning, or word sounds.' Our goal is to develop criteria for identifying high-risk patients on brain scan while they are hospitalized. Fundamental to effective intervention is early identification of reading problems. 'To identify people early on, we are looking at areas of brain damage associated with aphasia and type of reading difficulties.'
Source: EurekAlert! - Medicine and Health - January 24, 2018 Category: International Medicine & Public Health Source Type: news
Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study
Publication date: February 2018 Source:The Lancet Neurology, Volume 17, Issue 2 Author(s): Marian Galovic, Nico Döhler, Barbara Erdélyi-Canavese, Ansgar Felbecker, Philip Siebel, Julian Conrad, Stefan Evers, Michael Winklehner, Tim J von Oertzen, Hans-Peter Haring, Anna Serafini, Giorgia Gregoraci, Mariarosaria Valente, Francesco Janes, Gian Luigi Gigli, Mark R Keezer, John S Duncan, Josemir W Sander, Matthias J Koepp, Barbara Tettenborn Background Stroke is one of the leading causes of acquired epilepsy in adults. An instrument to predict whether people are at high risk of developing post-stroke seizures is not availab...
Source: The Lancet Neurology - January 18, 2018 Category: Neurology Source Type: research
The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study
Publication date: Available online 10 January 2018 Source:The Lancet Neurology Author(s): Mark A Rodrigues, Neshika Samarasekera, Christine Lerpiniere, Catherine Humphreys, Mark O McCarron, Philip M White, James A R Nicoll, Cathie L M Sudlow, Charlotte Cordonnier, Joanna M Wardlaw, Colin Smith, Rustam Al-Shahi Salman Background Identification of lobar spontaneous intracerebral haemorrhage associated with cerebral amyloid angiopathy (CAA) is important because it is associated with a higher risk of recurrent intracerebral haemorrhage than arteriolosclerosis-associated intracerebral haemorrhage. We aimed to develop a predict...
Source: The Lancet Neurology - January 12, 2018 Category: Neurology Source Type: research
Tribal Practices for Wellness In Indian Country
Funding for projects that support tribal practices that connect individuals and community to culture with the long-term goals of building resiliency; reducing morbidity and mortality due to heart disease, stroke, cancer, and diabetes; and reducing risk factors for all chronic disease among American Indians and Alaska Natives.
Source: HSR Information Central - January 5, 2018 Category: International Medicine & Public Health Source Type: news
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
Publication date: Available online 20 December 2017 Source:The Lancet Author(s): Philip M Bath, Lisa J Woodhouse, Jason P Appleton, Maia Beridze, Hanne Christensen, Robert A Dineen, Lelia Duley, Timothy J England, Katie Flaherty, Diane Havard, Stan Heptinstall, Marilyn James, Kailash Krishnan, Hugh S Markus, Alan A Montgomery, Stuart J Pocock, Marc Randall, Annemarei Ranta, Thompson G Robinson, Polly Scutt, Graham S Venables, Nikola Sprigg Background Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. W...
Source: The Lancet - December 21, 2017 Category: General Medicine Source Type: research
